Can The Medicines Company Rebound From A Phase III Blow?

The Medicines Company will focus development of its reversible antithrombotic cangrelor on use as a "bridging" drug for patients who must break from Sanofi Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) while undergoing surgery, after halting two Phase III trials in angioplasty patients because it was not showing approvable efficacy